MyFinsight
Home
Blog
About
Proceeds from standby
equity purchase...
$1,127,959
(31.71%↑ Y/Y)
Net cash provided by
financing activities
$1,127,959
(33.27%↑ Y/Y)
Net change in cash
and cash...
$500,656
(346.23%↑ Y/Y)
Canceled cashflow
$627,303
Increase in accrued
expenses and other...
$218,911
(-47.05%↓ Y/Y)
Net change in
unrealized depreciation...
$74,015
(168.87%↑ Y/Y)
Warrants
issued/(cancelled) to consultants
-$63,582
(35.17%↑ Y/Y)
Decrease in operating
lease right-of-use,...
-$19,921
(27.98%↑ Y/Y)
Imputed interest -
related party
$18,395
(-54.12%↓ Y/Y)
Fair value of options
issued for services
$10,157
(21.00%↑ Y/Y)
Depreciation expense
$7,102
(-38.35%↓ Y/Y)
Net cash used in
operating activities
-$598,695
(31.78%↑ Y/Y)
Net cash provided
(used in) by investing...
-$28,608
(-119.94%↓ Y/Y)
Canceled cashflow
$412,083
Net loss
-$909,535
(31.42%↑ Y/Y)
Purchase of fixed assets
$28,608
(656.23%↑ Y/Y)
(increase) in inventory
$59,835
Decrease in operating
lease liabilities,...
-$19,220
(33.03%↑ Y/Y)
(decrease) increase in
accounts payable
-$15,481
(-144.85%↓ Y/Y)
(increase) decrease
prepaid expenses
$6,707
(149.65%↑ Y/Y)
Back
Back
Cash Flow
Kraig Biocraft Laboratories, Inc. (KBLB)
Kraig Biocraft Laboratories, Inc. (KBLB)
source: myfinsight.com